More than half of patients A1C returned to normal Lilly GIP/GLP-1 subjector astrogen Phase 3 clinical results

Eli Lilly and Company today announced that its glucose-dependent insulin-promoting polypeptide (GIP) and glutatrogen-like peptide-1 (GLP-1) subject double agonist, Tirzepatide, have obtained positive top-line results in a Phase 3 clinical trial called SURFASS-1.
after 40 weeks of treatment, tirzepatide significantly reduced glycation hemoglobin (A1C) levels and weight in adults with type 2 diabetes compared to the placebo group.
Tirzepatide is a weekly injection of GIP and GLP-1-1 subjects that integrate the effects of two types of bowel insulin into a molecule, representing a new approach to the treatment of type 2 diabetes.
GIP is a hormone that may supplement the role of GLP-1 subjectors.
In preclinical models, GIP has been shown to reduce intake and increase energy consumption, resulting in weight loss, which, when used in union with GLP-1 vector agonists, may have a greater impact on glucose levels and weight.
54.2% of patients who participated in the SURPASS-1 clinical trial were first-time patients, with a relatively short course of diabetes (4.7 years), a baseline A1C level of 7.9% and a baseline weight of 85.9 kg.
the efficacy and safety of 3 different doses (5 mg, 10 mg and 15 mg) of tirzepatide in the SURPASS-1 clinical trial.
test results showed that all doses of tirzepatide reduced the patient's A1C and body weight compared to the baseline.
the highest dose of tirzepatide reduced the patient's A1C level by 2.07% and by 9.5 kg (11.0%).
51.7 percent of patients in this group had A1C levels below 5.7 percent, which was observed in people without diabetes.
data on the efficacy of Tirzepatide (Photo source: Reference 1) "Tirzepatide brought significant A1C levels and weight loss to people with type 2 diabetes in this trial.
, lead researcher on SURPASS-1 and director of the Dallas Diabetes Research Center, said, "This study boldly uses the unique endpoint of assessing A1C levels."
Not only did nearly 90 percent of all subjects who used tirzepatide meet the standard of less than 7 percent (the standard recommended by the American Diabetes Association for diabetics), but more than half of those taking the highest dose had A1C levels of less than 5.7 percent, the level of the diabetic-free population.
"Tirzepatide's type 2 diabetes clinical development program (Photo: Lilly.com) Tirzepatide is one of Lilly's key research and development projects in the field of diabetes, and the company's SURPASS clinical development program includes several clinical trials that will compare the efficacy and safety of tirzepatide monotherapy with other type 2 diabetes treatments.
is expected to file regulatory applications worldwide by 2022.
references: s tirzepatide largely reduced A1C and body weight in people with type 2 diabetes. Retrieved December 9, 2020, from